Chardan Capital Believes Amicus (NASDAQ: FOLD) Won’t Stop Here

By Carrie Williams

In a report released yesterday, Gbola Amusa from Chardan Capital maintained a Buy rating on Amicus (NASDAQ: FOLD), with a price target of $16.50. The company’s shares opened today at $13.34, close to its 52-week high of $14.37.

According to TipRanks.com, Amusa is a 1-star analyst with an average return of -0.3% and a 48.1% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma Corporation, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.

Currently, the analyst consensus on Amicus is Strong Buy and the average price target is $16.50, representing a 23.7% upside.

In a report released yesterday, Cowen & Co. also assigned a Buy rating to the stock with a $18 price target.

The company has a one year high of $14.37 and a one year low of $4.41. Currently, Amicus has an average volume of 3.8M.

Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Amicus Therapeutics, Inc. is a biotechnology company, which is engaged in the discovery, development and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease.